Glycomics Is THE Answer to Cancer for Prevention, Detection, and Diagnosis

The report states: Most FDA-approved cancer biomarkers are glycoproteins, but little is known about how their glycan structures are altered in cancer where diagnostic performance could be greatly improved. This experimental data is available at MIT.

The purpose for the study was to attract special scientists to exploit fundamental aspects of cancer biology; and, to establish a core of integrated glycobiologists to facilitate the development of cancer glycobiology for presentation and diagnostic applications.

One point in the report said that incentives are needed to attract the leading glycobiologist experts to do cancer research with defined clinical goals. The problem, according to the report, is that traditional funding mechanisms are not suited for an emerging field.

The Mission of the NIH/NCI study was to elucidate the structure and function of glycans that contribute to oncogenesis. And, to exploit aberrant glycosylation in cancer for the development of translational applications for cancer prevention, detection, and diagnosis.

This influx of talent is a game changer for fighting cancer. The best and brightest are coming to Texas and Houston. These established researchers are adding enormous talent to Baylor College of Medicine, Methodist Research Institute, Rice University, University of Texas MD Anderson Cancer Center, University of Texas - Austin, San Antonio and Southwestern Medical Center.

Houston is the Medical Capitol of the world and MD Anderson is the leading cancer treatment center. A few years ago an oncologist at MD Anderson explained to me that a doctor friend in Boston told him that glycomics was the future of medicine. Glycoproteins are now proven to be the bull's eye, the Rosetta Stone, of medicine and of all healthcare. Everything points to accelerated and expanded glycoprotein research, and rightfully so.

According to the NIH/NCI study, glycoproteins are good for diagnosing, monitoring, proving, reproving, developing billions of dollars in drugs, testing, and researching until the cows come home. Perhaps in another, always another, ten to twenty years, we will have a cancer cure.

Measuring the quality and quantity of glycoproteins on the cell surface is an excellent diagnostic approach because the lower the glycoprotein count, the greater the cancer risk. Healthy cells are sugar coated with glycoproteins while cancer cells are bald. Misfolding of proteins with specific sugars is the cause for poor quality and quantity of glycoproteins. Learning how to help properly fold proteins is the future of medicine and healthcare.

Bald cells will kill you. Healthy cells, clothed in fur like glycoproteins, give you life.

Yes, glycoprotein technology IS the bull's eye but perhaps the target is placed over the wrong objective. The traditional medical target is still over symptoms and drug treatment. In the process many are helped but we can do so much more if we simply move the target.

For more information about Poultry Diagnostic ,Poultry Serology,Aflatoxin Test and Bursal Test please visit my website.